Fourteen years ago, semaglutide’s older cousin (Ozempic and Wegovy) entered the market. The drug liraglutide is sold under brand names Victoria AND Saxenda.

Patents for Victoza and Saxenda now expired. Likewise other pharmaceutical corporations working develop “generic” versions. These are prone to be a fraction of the running costs, i.e around 400 Australian dollars monthly.

So how does liraglutide compare to semaglutide?

How do these medicines work?

Liraglutide was not originally developed as a slimming treatment. Like semaglutide (Ozempic), it originally treated type 2 diabetes.

Liraglutide and semaglutide medications are often called GLP-1 mimetics, which suggests they mimic the natural hormone GLP-1. This hormone is released from the small intestine in response to food and works in several ways to enhance the best way the body handles glucose (sugar).

How do they stop hunger?

Liraglutide works in several areas of the unconscious a part of the brain, particularly the hypothalamus, which controls metabolism, and in parts of the brainstem answerable for transmitting information to the hypothalamus in regards to the body’s dietary status.

His actions seem to cut back hunger in two alternative ways. First, it helps you are feeling full faster, making smaller meals more satisfying. Second, it changes yourmotivational meaning” towards food, which suggests it reduces the quantity of food you’re on the lookout for.

The original formulation of liraglutide, intended for the treatment of type 2 diabetes, was marketed as Victoza. Its ability to cause weight reduction was obvious soon after entering the market.

Shortly thereafter, a stronger preparation called Saxenda appeared releasedwhich was intended for weight reduction in obese people.

How much weight are you able to lose using liraglutide?

People react otherwise and shed weight to various degrees. But here we will highlight the typical weight reduction that users can expect. Some will lose more (sometimes rather more), some will lose less, and a small proportion will not respond.

The first GLP-1 mimetic drug was exenatide (Bayetta). It continues to be available for the treatment of type 2 diabetes, but there are currently no generics. Exenatide does provide some weight reduction, but it is sort of modest, normally around 3-5% body weight.

In the case of liraglutide, people taking the drug to treat obesity will use a stronger drug (Saxenda), which normally gives roughly 10% weight reduction.

Semaglutide in a stronger form called Wegovy normally causes 15% weight reduction.

The newest GLP-1 mimetic drug available on the market, tyrzepatid (Mounjaro for type 2 diabetes and Zepbound for weight reduction), causes weight reduction of roughly 25% body weight.

What happens if you stop taking them?

Despite the effectiveness of those drugs in weight reduction, they don’t appear to vary the patient’s established weight.

Therefore, in lots of cases, when people stop taking them, they experience: rebound to original weight.

What is the dose and how often does it have to be taken?

Liraglutide (Victoza) for type 2 diabetes is identical drug as Saxenda for weight reduction, but Saxenda has the next dose.

Although the goal of motion of every preparation is identical (GLP-1 receptor), as a way to control glucose levels in type 2 diabetes, liraglutide must reach (primarily) the pancreas.

However, to realize weight reduction, it must reach a part of the brain. This means crossing the blood-brain barrier – and never everyone does this, which suggests you might have to take more.

All current formulations of the GLP-1 mimetic are injectable. This will not change when generics of liraglutide appear available on the market.

However, they differ within the frequency of injection. Liraglutide is given as an injection once a day, while semaglutide and tirzepatide are given once per week. (This makes semaglutide and tyrzepatide rather more attractive, but we can’t see semaglutide as generics until 2033.)

What are the negative effects?

Because all of those drugs have the identical purpose within the body, they mostly have the identical negative effects.

The most typical are various gastrointestinal disorders, incl nausea, vomiting, flatulence, constipation and diarrhea. These occur partly because these medications slow the passage of food from the stomach, but they will generally be managed by slowly increasing the dose.

Recent clinical data suggests that slowing gastric emptying can be and will be problematic for some people increase the danger of food entering the lungs during surgerysubsequently it is vital to inform your doctor in case you are taking any of those medicines.

Since these are injections, they also can result in injection site reactions.

Several cases of thyroid disease and pancreatitis have been reported during clinical trials. However, it is just not clear whether this may be the case attributed to drugs that mimic GLP-1.

Drugs that mimic GLP-1 have been found to work in animals negatively affect the event of the embryo. There is currently no data from controlled clinical trials regarding their use while pregnant, nonetheless animal data suggest that these drugs mustn’t be used while pregnant.

Who can profit from them?

GLP-1 mimetic drugs used for weight reduction (Vega, SaxendaZepbound/Mounjaro) are approved to be used by obese people and are intended to be used only together with weight loss plan and exercise.

These drugs must be prescribed by a health care provider and are usually not covered by the Pharmaceutical Benefits Scheme for obesity, which is considered one of the explanations they’re expensive. However, over time, generic versions of liraglutide will likely develop into cheaper.

After updating fans on how she’s approaching postpartum fitness for the third time around, Cardi B gave an update on her butt injection reversal.

In a recent Instagram live, the rapper and mother of three, who gave birth in September, shared that she went under the knife earlier this 12 months.

“In January, right after filming ‘Like What,’ I went into surgery. I had a few more injections removed from my butt. Because, you know, it takes a round to remove butt injections. I had several injections removed from my butt. I also went to get treatment for some things related to fibrosis,” Cardi said, per People Magazine.

The “Bongos” rapper said during a previous Instagram Live event in December 2022 that she had 95 percent of previously injected biopolymers removed from her buttocks in August. Biopolymers are the silicone injections Cardi was talking about GQ got into the basement in 2014 for $800.

However, Cardi B isn’t the only one that has had cosmetic surgery reversed. Several famous women, including Blac Chyna, Ayesha Curry and SZA, have also recently spoken out about having their teeth extracted and reversing the procedure. Plastic surgeons are also noticing a major change in patients’ desires.

According to the latest report prepared by American Society of Plastic Surgery“In 2023, there has been a continued movement towards a more natural and athletic silhouette.” The organization has named the latest trendy aesthetic “Ballet Body.”

Featured Stories

More and more patients are choosing procedures aimed toward “slimming” and reversing the Brazilian butt lift and extreme augmentations which have turn out to be fashionable over the last decade or more. The organization said liposuction remained the most in-demand procedure last 12 months, with almost 350,000 procedures performed, a seven percent increase over 2022. While breast augmentation saw a two percent increase and breast lift a seven percent increase, implant removals breasts increased by nine percent.

Trends in body aesthetics are consistently changing. This data comes as the availability and use of GLP-1 drugs comparable to Ozempic and Wegovy have increased, which many individuals in Hollywood and beyond have turned to in large numbers for his or her weight reduction potential. Experts and doctors agree that the growing popularity of drugs is changing trends.

In an interview with the Washington Post, a dietitian Nyemb-Diopa monkey stated that they felt that society was “going backwards”.

“Women’s bodies in society are products, and like all products on the market, they go through a cycle: starting, then maturing,” Nyemb-Diop said publication. “And I think the ‘BBL body’ was mature.”

She added: “The cycle was ready for the introduction of another body – and at the same time, Ozempic was there.”

October is breast cancer awareness month. Black women are roughly 40% more more likely to die from breast cancer than white women and are more likely than white women to be diagnosed with breast cancer at younger ages, in later stages, and for more aggressive types of breast cancer.

Earlier this month US Food and Drug Administration issued a final rule that requires summaries of mammography results, including a press release of breast density, to be prepared at the start. This rule could save lives within the Black community because Black women are inclined to have denser breast tissue than white women, which might increase the risk of developing breast cancer and make it harder to identify early symptoms on a mammogram.

Susan G CommentsThe world’s leading breast cancer organization issued a press release on the new ruling: “Knowledge is power, and all women can now have informed conversations with their doctors about the right screening plan for them based on the factors that influence their risk of breast cancer.” including breast density,” Molly Guthrie, vp of policy and advocacy.

“Knowledge is power, and all women can now have informed conversations with their health care providers about the screening plan that is right for them based on factors that influence breast cancer risk, including breast density,” said Molly Guthrie, vp of policy and advocacy at Susan G. Komen. “This may mean that additional tests are recommended to accurately detect breast cancer.”

Breast density is a mammogram measurement of fibrous and glandular tissue, including the lobules and ducts that produce and transport milk, in comparison with fatty tissue within the breast. Dense breasts are common, affecting roughly 40-50% of U.S. women aged 40-74. However, breast density is just one factor that affects a girl’s risk of breast cancer. Age, gender, genetics, family health history and lifestyle aspects all play a big role in an individual’s overall risk. Women with very dense breasts are 4-5 times more more likely to develop breast cancer, and dense breast tissue can hide lumps on mammograms. Komen encourages women to refer to their health care providers about their breast density and whether additional breast imaging could also be appropriate for them.

By September 10, 2024, mammogram reports must include an assessment of breast density. The reports will include general findings – the breasts are dense or the breasts are not dense – and extra details concerning the density level:

• Breasts are almost completely fatty (not dense)
• Breasts have scattered areas of fibroglandular density (not dense)
• Breasts are heterogeneously dense, which can obscure small masses (dense)
• Breasts are extremely dense, which reduces the sensitivity of mammography (dense)

Thanks to the Affordable Care Act (ACA), tens of millions of people have universal access to annual mammograms starting at age 40, without having to share the price for the patient. However, let’s assume that breast imaging is required along with screening mammography. When this happens, patients often face out-of-pocket costs of lots of and even hundreds of dollars, which poses a big financial barrier to accessing the care they need.

“We want everyone to know that dense breast tissue itself does not require additional imaging – it is just one risk factor for breast cancer,” Guthrie added. “For those who need imaging beyond mammography, out-of-pocket costs are often a barrier. That’s why we have advocated for state and federal legislation to eliminate these expenses. We have the technology to detect breast cancer earlier and save lives, and financial barriers should not stand in the way. It is crucial to understand and affordably access the breast imaging tests they need based on their individual risk.”

“The new federal breast density regulations provide women across the United States with meaningful and more consistent information concerning the density of their breasts. Women with very dense breasts are 4-5 times more more likely to develop breast cancer than women with fatty breasts, and a few studies show that black women are more more likely to have dense breasts. Breast cancer health disparities have a profound impact on Black women, and having more information may help women speak up for themselves and have informed conversations with their healthcare providers. Susan G. Komen encourages women to refer to their health care providers about breast density, in addition to their risk of developing breast cancer, and to contemplate which breast imaging test is correct for them,” said Natasha Mmeje, director of community education and outreach at Susan G. Komem.

The Susan G. Komen Center for Public Policy is working with state and federal lawmakers to pass laws that may eliminate out-of-pocket spending on imaging tests beyond screening mammography. So far 26 states have eliminated out-of-pocket costs patients covered by state medical health insurance plans for diagnostics and/or additional imaging tests. At the federal level Access to the act on breast cancer diagnosis has been introduced within the U.S. House of Representatives and Senate, but is unlikely to be passed on this Congress. Komen calls for legislative motion to remove financial and administrative barriers to breast imaging, ensuring all patients can follow advisable screening guidelines based on their risk.

Additionally, Komen’s ongoing health equity initiative within the Black community, Stand for HER. This health equity revolution is a targeted initiative to scale back breast cancer disparities among the many Black community by 25%, starting in U.S. metropolitan areas where disparities are highest; read more Here.